Diseases /
Melanoma
Back to Diseases List
Associated Genetic Biomarkers
Overview
NCI Definition: A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain. [1]
Melanomas most frequently harbor alterations in BRAF, CDKN2A, NRAS, TP53, and NF1 [2].
BRAF Mutation, BRAF Exon 15 Mutation, BRAF Codon 600 Missense, NRAS Mutation, and BRAF V600E are the most common alterations in melanoma [2].
Biomarker-Directed Therapies
Of the biomarker-directed therapies for melanoma, 7 are FDA-approved in at least one setting and 9 have NCCN guidelines in at least one setting [3].
Binimetinib +
Disease is predicted to be sensitive: -
| Biomarker Criteria: | Clinical Setting(s): Metastatic (NCCN) |
| Note: Recommended for NRAS mutated tumors that have progressed after prior immune checkpoint inhibitor therapy (category 2B). |
Dabrafenib +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (FDA, NCCN) |
| Note: According to NCCN, if BRAF/MEK inhibitor combination therapy is contraindicated, BRAF-inhibitor monotherapy is an option, especially in patients who are not appropriate candidates for checkpoint immunotherapy. |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
| Note: According to NCCN, if BRAF/MEK inhibitor combination therapy is contraindicated, BRAF-inhibitor monotherapy is an option, especially in patients who are not appropriate candidates for checkpoint immunotherapy. |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (NICE, BNF, SMC) |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (NICE, SMC) |
| Note: According to NCCN, if BRAF/MEK inhibitor combination therapy is contraindicated, BRAF-inhibitor monotherapy with dabrafenib is recommended, especially in patients who are not appropriate candidates for checkpoint immunotherapy. |
Encorafenib +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
| Note: According to NCCN, if BRAF/MEK inhibitor combination therapy is contraindicated, BRAF-inhibitor monotherapy is an option, especially in patients who are not appropriate candidates for checkpoint immunotherapy. |
Imatinib +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: |
Clinical Setting(s): Metastatic (NCCN, MCG) |
Nilotinib +
Disease is predicted to be sensitive: -
Sorafenib +
Sunitinib +
Trametinib +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (FDA) |
| Note: Trametinib is FDA approved for single-agent use to treat patients with unresectable or metastatic melanoma with BRAF V600E/K; however, trametinib monotherapy is no longer an NCCN-recommended treatment option due to relatively poor efficacy compared with BRAF inhibitor monotherapy and BRAF/MEK inhibitor combination therapy. |
Vemurafenib +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (FDA, NCCN) |
| Note: According to NCCN, if BRAF/MEK inhibitor combination therapy is contraindicated, BRAF-inhibitor monotherapy is an option, especially in patients who are not appropriate candidates for checkpoint immunotherapy. |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
| Note: According to NCCN, if BRAF/MEK inhibitor combination therapy is contraindicated, BRAF-inhibitor monotherapy is an option, especially in patients who are not appropriate candidates for checkpoint immunotherapy. |
Atezolizumab + Cobimetinib + Vemurafenib +
Disease is predicted to be sensitive: -
Binimetinib + Encorafenib +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (FDA, NCCN) |
| Note: Approved for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
| Note: Recommended by NCCN if a BRAF V600 activating mutation is present. |
Cobimetinib + Vemurafenib +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (FDA, NCCN) |
| Note: According to NCCN, BRAF/MEK inhibitor combination is preferred over BRAF inhibitor monotherapy based on results from phase III trials in the first-line setting showing improved outcomes and similar risk of toxicity |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
| Note: According to NCCN, BRAF/MEK inhibitor combination is preferred over BRAF inhibitor monotherapy based on results from phase III trials in the first-line setting showing improved outcomes and similar risk of toxicity |
Dabrafenib + Pembrolizumab + Trametinib +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
| Note: NCCN recommended as first line therapy (Category 2B). |
Dabrafenib + Trametinib +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Adjuvant (FDA, NCCN), Metastatic (FDA, NCCN) |
| Note: According to NCCN, BRAF/MEK inhibitor combination is preferred over BRAF inhibitor monotherapy based on results from phase III trials in the first-line setting showing improved outcomes and similar risk of toxicity. |
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Adjuvant (NCCN), Metastatic (NCCN) |
| Note: According to NCCN, BRAF/MEK inhibitor combination is preferred over BRAF inhibitor monotherapy based on results from phase III trials in the first-line setting showing improved outcomes and similar risk of toxicity. |
Clinical Trials
There are 472 clinical trials for melanoma, of which 333 are open and 139 are completed or closed. Of the trials that contain melanoma as an inclusion criterion, 8 are early phase 1 (6 open), 174 are phase 1 (116 open), 110 are phase 1/phase 2 (83 open), 153 are phase 2 (110 open), 3 are phase 2/phase 3 (3 open), 18 are phase 3 (10 open), 1 is phase 4 (1 open), and 5 are no phase specified (4 open).
BRAF, HLA-A*02, and KIT are the most frequent gene inclusion criteria for melanoma clinical trials [3].
Pembrolizumab, nivolumab, and ipilimumab are the most common interventions in melanoma clinical trials.
Significant Genes in Melanoma
AKT1 +
AKT1 is altered in 1.26% of melanoma patients [2].
AKT1 is an inclusion eligibility criterion in 3 clinical trials for melanoma, of which 3 are open and 0 are closed. Of the trials that contain AKT1 status and melanoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 1 is phase 2 (1 open) [3].
ARAF +
ARAF is altered in 2.42% of melanoma patients [2].
ARAF is an inclusion eligibility criterion in 5 clinical trials for melanoma, of which 5 are open and 0 are closed. Of the trials that contain ARAF status and melanoma as inclusion criteria, 3 are phase 1 (3 open) and 2 are phase 1/phase 2 (2 open) [3].
BRAF +
BRAF is altered in 35.7% of melanoma patients [2].
BRAF is an inclusion eligibility criterion in 106 clinical trials for melanoma, of which 59 are open and 47 are closed. Of the trials that contain BRAF status and melanoma as inclusion criteria, 2 are early phase 1 (2 open), 32 are phase 1 (15 open), 20 are phase 1/phase 2 (12 open), 46 are phase 2 (26 open), and 6 are phase 3 (4 open) [3].
Dabrafenib, vemurafenib, binimetinib, encorafenib, cobimetinib, trametinib, atezolizumab, and pembrolizumab have evidence of efficacy in patients with BRAF mutation in melanoma [3].
BTRC +
BTRC is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains BTRC status and melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].
CDKN2A +
CDKN2A is altered in 24.64% of melanoma patients [2].
CDKN2A is an inclusion eligibility criterion in 5 clinical trials for melanoma, of which 4 are open and 1 is closed. Of the trials that contain CDKN2A status and melanoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [3].
CRKL +
CRKL is altered in 2.81% of melanoma patients [2].
CRKL is an inclusion eligibility criterion in 5 clinical trials for melanoma, of which 5 are open and 0 are closed. Of the trials that contain CRKL status and melanoma as inclusion criteria, 2 are phase 1 (2 open) and 3 are phase 1/phase 2 (3 open) [3].
DVL1 +
DVL1 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains DVL1 status and melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].
EZH2 +
EZH2 is altered in 3.48% of melanoma patients [2].
EZH2 is an inclusion eligibility criterion in 2 clinical trials for melanoma, of which 1 is open and 1 is closed. Of the trials that contain EZH2 status and melanoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [3].
FZD1 +
FZD1 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains FZD1 status and melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD10 +
FZD10 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains FZD10 status and melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD2 +
FZD2 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains FZD2 status and melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD3 +
FZD3 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains FZD3 status and melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD4 +
FZD4 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains FZD4 status and melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD5 +
FZD5 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains FZD5 status and melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD6 +
FZD6 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains FZD6 status and melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD7 +
FZD7 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains FZD7 status and melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD8 +
FZD8 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains FZD8 status and melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD9 +
FZD9 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains FZD9 status and melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].
HDAC2 +
HDAC2 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains HDAC2 status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
HRAS +
HRAS is altered in 1.82% of melanoma patients [2].
HRAS is an inclusion eligibility criterion in 9 clinical trials for melanoma, of which 7 are open and 2 are closed. Of the trials that contain HRAS status and melanoma as inclusion criteria, 6 are phase 1 (4 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].
KIT +
KIT is altered in 6.55% of melanoma patients [2].
KIT is an inclusion eligibility criterion in 13 clinical trials for melanoma, of which 7 are open and 6 are closed. Of the trials that contain KIT status and melanoma as inclusion criteria, 3 are phase 1 (2 open), 2 are phase 1/phase 2 (1 open), 7 are phase 2 (4 open), and 1 is phase 3 (0 open) [3].
Imatinib, nilotinib, sorafenib, and sunitinib have evidence of efficacy in patients with KIT mutation in melanoma [3].
KRAS +
KRAS is altered in 2.9% of melanoma patients [2].
KRAS is an inclusion eligibility criterion in 12 clinical trials for melanoma, of which 9 are open and 3 are closed. Of the trials that contain KRAS status and melanoma as inclusion criteria, 9 are phase 1 (6 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].
LIG3 +
LIG3 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains LIG3 status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
LRP5 +
LRP5 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains LRP5 status and melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].
MAP2K1 +
MAP2K1 is altered in 5.66% of melanoma patients [2].
MAP2K1 is an inclusion eligibility criterion in 6 clinical trials for melanoma, of which 5 are open and 1 is closed. Of the trials that contain MAP2K1 status and melanoma as inclusion criteria, 2 are phase 1 (2 open), 3 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].
MAP2K2 +
MAP2K2 is altered in 2.76% of melanoma patients [2].
MAP2K2 is an inclusion eligibility criterion in 4 clinical trials for melanoma, of which 4 are open and 0 are closed. Of the trials that contain MAP2K2 status and melanoma as inclusion criteria, 2 are phase 1 (2 open) and 2 are phase 1/phase 2 (2 open) [3].
MAP2K4 +
MAP2K4 is altered in 1.6% of melanoma patients [2].
MAP2K4 is an inclusion eligibility criterion in 4 clinical trials for melanoma, of which 4 are open and 0 are closed. Of the trials that contain MAP2K4 status and melanoma as inclusion criteria, 2 are phase 1 (2 open) and 2 are phase 1/phase 2 (2 open) [3].
MAP3K1 +
MAP3K1 is altered in 3.96% of melanoma patients [2].
MAP3K1 is an inclusion eligibility criterion in 5 clinical trials for melanoma, of which 4 are open and 1 is closed. Of the trials that contain MAP3K1 status and melanoma as inclusion criteria, 3 are phase 1 (2 open) and 2 are phase 1/phase 2 (2 open) [3].
MAPK1 +
MAPK1 is altered in 1.84% of melanoma patients [2].
MAPK1 is an inclusion eligibility criterion in 4 clinical trials for melanoma, of which 4 are open and 0 are closed. Of the trials that contain MAPK1 status and melanoma as inclusion criteria, 2 are phase 1 (2 open) and 2 are phase 1/phase 2 (2 open) [3].
MCPH1 +
MCPH1 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains MCPH1 status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
MTOR +
MTOR is altered in 6.48% of melanoma patients [2].
MTOR is an inclusion eligibility criterion in 3 clinical trials for melanoma, of which 3 are open and 0 are closed. Of the trials that contain MTOR status and melanoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 1 is phase 2 (1 open) [3].
MYCN +
MYCN is altered in 3.74% of melanoma patients [2].
MYCN is an inclusion eligibility criterion in 2 clinical trials for melanoma, of which 2 are open and 0 are closed. Of the trials that contain MYCN status and melanoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
NF1 +
NF1 is altered in 24.25% of melanoma patients [2].
NF1 is an inclusion eligibility criterion in 6 clinical trials for melanoma, of which 5 are open and 1 is closed. Of the trials that contain NF1 status and melanoma as inclusion criteria, 3 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].
NRAS +
NRAS is altered in 23.15% of melanoma patients [2].
NRAS is an inclusion eligibility criterion in 18 clinical trials for melanoma, of which 9 are open and 9 are closed. Of the trials that contain NRAS status and melanoma as inclusion criteria, 11 are phase 1 (6 open), 5 are phase 1/phase 2 (2 open), 1 is phase 2 (1 open), and 1 is phase 3 (0 open) [3].
Binimetinib has evidence of efficacy in patients with NRAS mutation in melanoma [3].
PCNA +
PCNA is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains PCNA status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
PDGFRA +
PDGFRA is altered in 6.71% of melanoma patients [2].
PDGFRA is an inclusion eligibility criterion in 4 clinical trials for melanoma, of which 4 are open and 0 are closed. Of the trials that contain PDGFRA status and melanoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].
PIK3CA +
PIK3CA is altered in 3.85% of melanoma patients [2].
PIK3CA is an inclusion eligibility criterion in 5 clinical trials for melanoma, of which 3 are open and 2 are closed. Of the trials that contain PIK3CA status and melanoma as inclusion criteria, 2 are phase 1 (0 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].
PIK3R1 +
PIK3R1 is altered in 2.58% of melanoma patients [2].
PIK3R1 is an inclusion eligibility criterion in 3 clinical trials for melanoma, of which 2 are open and 1 is closed. Of the trials that contain PIK3R1 status and melanoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 1/phase 2 (2 open) [3].
PTEN +
PTEN is altered in 8.17% of melanoma patients [2].
PTEN is an inclusion eligibility criterion in 6 clinical trials for melanoma, of which 4 are open and 2 are closed. Of the trials that contain PTEN status and melanoma as inclusion criteria, 2 are phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (1 open) [3].
RAF1 +
RAF1 is altered in 3.89% of melanoma patients [2].
RAF1 is an inclusion eligibility criterion in 6 clinical trials for melanoma, of which 6 are open and 0 are closed. Of the trials that contain RAF1 status and melanoma as inclusion criteria, 3 are phase 1 (3 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].
RET +
RET is altered in 6.15% of melanoma patients [2].
RET is an inclusion eligibility criterion in 4 clinical trials for melanoma, of which 3 are open and 1 is closed. Of the trials that contain RET status and melanoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (1 open) [3].
RFC1 +
RFC1 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains RFC1 status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
RFC2 +
RFC2 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains RFC2 status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
RFC3 +
RFC3 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains RFC3 status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
RFC4 +
RFC4 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains RFC4 status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
RFC5 +
RFC5 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains RFC5 status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
RPA2 +
RPA2 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains RPA2 status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
RPA3 +
RPA3 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains RPA3 status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
RPA4 +
RPA4 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains RPA4 status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
RSPO1 +
RSPO1 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains RSPO1 status and melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].
SHFM1 +
SHFM1 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains SHFM1 status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
SRC +
SRC is altered in 1.39% of melanoma patients [2].
SRC is an inclusion eligibility criterion in 4 clinical trials for melanoma, of which 4 are open and 0 are closed. Of the trials that contain SRC status and melanoma as inclusion criteria, 2 are phase 1 (2 open) and 2 are phase 1/phase 2 (2 open) [3].
SSBP1 +
SSBP1 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains SSBP1 status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
TSC1 +
TSC1 is altered in 4.56% of melanoma patients [2].
TSC1 is an inclusion eligibility criterion in 3 clinical trials for melanoma, of which 3 are open and 0 are closed. Of the trials that contain TSC1 status and melanoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 1 is phase 2 (1 open) [3].
TSC2 +
TSC2 is altered in 5.31% of melanoma patients [2].
TSC2 is an inclusion eligibility criterion in 3 clinical trials for melanoma, of which 3 are open and 0 are closed. Of the trials that contain TSC2 status and melanoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 1 is phase 2 (1 open) [3].
WNT1 +
WNT1 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains WNT1 status and melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].
Disease Details
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
